ES2171222T3 - Compuestos de eter heterociclico de 3-piridiloxialquilo utiles para regular la transmision sinaptica quimica. - Google Patents

Compuestos de eter heterociclico de 3-piridiloxialquilo utiles para regular la transmision sinaptica quimica.

Info

Publication number
ES2171222T3
ES2171222T3 ES96914786T ES96914786T ES2171222T3 ES 2171222 T3 ES2171222 T3 ES 2171222T3 ES 96914786 T ES96914786 T ES 96914786T ES 96914786 T ES96914786 T ES 96914786T ES 2171222 T3 ES2171222 T3 ES 2171222T3
Authority
ES
Spain
Prior art keywords
compounds
piridiloxialquilo
heterociclico
eter
chemical synthetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96914786T
Other languages
English (en)
Inventor
Mark W Holladay
Nan-Horng Lin
Keith B Ryther
Yun He
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/474,873 external-priority patent/US5948793A/en
Priority claimed from US08/485,537 external-priority patent/US5914328A/en
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Application granted granted Critical
Publication of ES2171222T3 publication Critical patent/ES2171222T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

NUEVOS COMPUESTOS DE ETER HETEROCICLICO DE 3 QUILO DE FORMULA (I) EN LOS QUE * ES UN CENTRO QUIRAL Y N, X, R SUP,1}, R SUP,2}, A Y B SON DEFINIDOS ESPECIFICAMENTE, QUE SON UTILES EN EL CONTROL DE LA TRANSMISION SINAPTICA QUIMICA; COMPOSICIONES TERAPEUTICAMENTE EFECTIVAS DE LOS MISMOS Y EL USO DE DICHAS COMPOSICIONES PARA CONTROLAR SELECTIVAMENTE LA TRANSMISION SINAPTICA EN MAMIFEROS.
ES96914786T 1995-06-07 1996-05-28 Compuestos de eter heterociclico de 3-piridiloxialquilo utiles para regular la transmision sinaptica quimica. Expired - Lifetime ES2171222T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/474,873 US5948793A (en) 1992-10-09 1995-06-07 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling neurotransmitter release
US08/485,537 US5914328A (en) 1992-10-09 1995-06-07 Heterocyclic ether compounds useful in controlling neurotransmitter release

Publications (1)

Publication Number Publication Date
ES2171222T3 true ES2171222T3 (es) 2002-09-01

Family

ID=27044605

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96914786T Expired - Lifetime ES2171222T3 (es) 1995-06-07 1996-05-28 Compuestos de eter heterociclico de 3-piridiloxialquilo utiles para regular la transmision sinaptica quimica.

Country Status (14)

Country Link
EP (1) EP0846114B1 (es)
JP (2) JP4060357B2 (es)
KR (1) KR100484331B1 (es)
AT (1) ATE210130T1 (es)
AU (1) AU709784B2 (es)
CA (1) CA2223062C (es)
DE (1) DE69617701T2 (es)
DK (1) DK0846114T3 (es)
ES (1) ES2171222T3 (es)
HK (1) HK1011866A1 (es)
IL (1) IL118279A (es)
MX (1) MX9709721A (es)
PT (1) PT846114E (es)
WO (1) WO1996040682A1 (es)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629325A (en) * 1996-06-06 1997-05-13 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
US6437138B1 (en) * 1996-06-06 2002-08-20 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
US6133253A (en) * 1996-12-10 2000-10-17 Abbott Laboratories 3-Pyridyl enantiomers and their use as analgesics
EP0950057B1 (en) * 1996-12-10 2002-11-13 Abbott Laboratories 3-pyridyl enantiomers and their use as analgesics
EP1357121A1 (en) * 1997-11-05 2003-10-29 Neurosearch A/S Azaring-ether deritatives and their use as nicotinic ach receptor modulators
EP1047690B1 (en) * 1997-12-19 2004-03-24 Abbott Laboratories Heterocyclic ether and thioether compounds useful in controlling chemical synaptic transmission
CA2317572A1 (en) 1998-04-02 1999-10-14 Jared Miller Wagner Pharmaceutical compositions and methods for use
US6362371B1 (en) 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
WO2000046193A2 (en) * 1999-02-03 2000-08-10 Schering Aktiengesellschaft Ether derivatives having neuronal activity
US6284779B1 (en) 1999-02-03 2001-09-04 Schering Aktiiengesellschaft Heteroaromatic compounds
US20010031771A1 (en) 1999-05-24 2001-10-18 Gary Maurice Dull Pharmaceutical compositions and methods for use
WO2001004091A1 (en) * 1999-07-09 2001-01-18 Ortho-Mcneil Pharmaceutical, Inc. Neurotrophic 2-azetidinecarboxylic acid derivatives, and related compositions and methods
US6656958B2 (en) 2000-02-02 2003-12-02 Abbott Laboratories Substituted pyridine compounds useful for controlling chemical synaptic transmission
US20010034357A1 (en) * 2000-02-02 2001-10-25 Nan-Horng Lin Substituted pyridine compounds useful for controlling chemical synaptic transmission
AU2002327340A1 (en) * 2001-07-31 2003-02-17 Virginia Commonwealth University 3-pyridylether rerivatives and their use as analgesics
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
AU2003245753B2 (en) 2002-07-05 2009-12-24 Targacept, Inc. N-aryl diazaspiracyclic compounds and methods of preparation and use thereof
AU2003254016A1 (en) 2002-07-19 2004-02-09 Catholic Healthcare West Methods and compositions relating to chimeric nicotinic receptor subunits
US7098331B2 (en) 2003-03-05 2006-08-29 Targacept, Inc. Arylvinylazacycloalkane compounds and methods of preparation and use thereof
US8580842B2 (en) 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
AU2005284908B2 (en) 2004-09-13 2011-12-08 Morningside Venture Investments Limited Biosynchronous transdermal drug delivery
EP1802601A1 (en) 2004-09-20 2007-07-04 Targacept, Inc. Azaspiroalkene and azapiroalkane compounds with nicotinic cholinergic receptor activity
US7459469B2 (en) 2004-11-10 2008-12-02 Targacept, Inc. Hydroxybenzoate salts of metanicotine compounds
UA88792C2 (ru) 2004-11-10 2009-11-25 Таргасепт, Інк. Гидроксибензоатные соли метаникотиновых соединений
AU2006283453A1 (en) 2005-08-22 2007-03-01 Targacept, Inc. Heteroaryl-substituted diazatricycloalkanes, methods for its preparation and use thereof
US20070184490A1 (en) * 2006-01-17 2007-08-09 Marleen Verlinden Neuronal nicotinic receptor ligands and their use
TW200800020A (en) * 2006-01-26 2008-01-01 Basf Ag Methods to use 3-pyridyl derivatives as pesticides
US8017785B2 (en) 2006-05-09 2011-09-13 Astrazeneca Ab Salt forms of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)y1]-4-penten 2-amine
TWI389889B (zh) 2006-05-09 2013-03-21 Targacept Inc （２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型
TWI404532B (zh) 2006-11-02 2013-08-11 Targacept Inc 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺
US8486979B2 (en) 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
US20080167286A1 (en) 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
UY30846A1 (es) 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
EP2112923A1 (en) 2007-01-22 2009-11-04 Targacept Inc. Intranasal, buccal, and sublingual administration of metanicotine analogs
TW200845977A (en) 2007-03-30 2008-12-01 Targacept Inc Sub-type selective azabicycloalkane derivatives
EP2322168A1 (en) 2007-04-02 2011-05-18 Parkinson's Institute Methods and Compositions for Reduction of Side Effects of Therapeutic Treatments
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
CN101883771A (zh) 2007-10-01 2010-11-10 科门蒂斯公司 作为α7-烟碱乙酰胆碱受体配体用于治疗阿尔茨海默氏病的奎宁环-4-基甲基1H-吲哚-3-甲酸酯衍生物
NZ586651A (en) 2007-12-07 2012-06-29 Abbott Gmbh & Co Kg 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases
MX2010006204A (es) 2007-12-07 2011-03-16 Abbott Gmbh & Co Kg Derivados de oxindol 5,6-disubstituidos y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
WO2010009775A1 (de) 2007-12-07 2010-01-28 Abbott Gmbh & Co. Kg Carbamat-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
JP5701607B2 (ja) 2007-12-07 2015-04-15 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー アミドメチル置換オキシインドール誘導体およびバソプレッシン依存性疾患の治療へのこれらの使用
US8383657B2 (en) 2007-12-21 2013-02-26 Abbott Laboratories Thiazolylidine urea and amide derivatives and methods of use thereof
US9463190B2 (en) 2008-03-31 2016-10-11 University Of South Florida Methods of treating disease-induced ataxia and non-ataxic imbalance
CN102216289A (zh) 2008-10-14 2011-10-12 塞扣吉尼克斯公司 烟碱乙酰胆碱受体配体及其用途
US9145396B2 (en) 2008-12-01 2015-09-29 Targacept, Inc. Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
MX2011005611A (es) 2008-12-01 2011-09-15 Targacept Inc Sintesis y formas de sales novedosas de (r)-5-((e)-2-(pirrolidin-3 -il-vinil)pirimidina.
TW201024283A (en) 2008-12-01 2010-07-01 Targacept Inc Synthesis and novel salt forms of (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
EP2435080A2 (en) 2009-05-29 2012-04-04 Abbott Laboratories Pharmaceutical compositions for the treatment of pain
KR20120120190A (ko) 2009-12-07 2012-11-01 타가셉트 인코포레이티드 신경원성 니코틴 아세틸콜린 수용체 리간드인 ３，６?디아자비시클로［３．１．１］헵탄
CN109662964A (zh) 2010-02-09 2019-04-23 约翰斯.霍普金斯大学 用于改善认知功能的方法和组合物
RU2012150449A (ru) 2010-05-20 2014-06-27 Астразенека Аб Новый способ получения арилзамещенных олефиновых аминов
EP2576496B1 (en) 2010-05-27 2017-03-08 Catalyst Biosciences, Inc. Nicotinic receptor non-competitive antagonists
WO2012125518A1 (en) 2011-03-14 2012-09-20 Targacept, Inc. Salt forms of 3 - cyclopropylcarbonyl - 3, 6 - diazabicyclo [3.1.1] heptane
WO2012129262A1 (en) 2011-03-23 2012-09-27 Targacept, Inc. Treatment of attention deficit/hyperactivity disease
TW201311698A (zh) 2011-08-22 2013-03-16 Targacept Inc 作為神經元菸鹼乙醯膽鹼受體配位體之１，４－二氮雜雙環［３．２．２］壬烷
CA2891122C (en) 2012-11-14 2021-07-20 The Johns Hopkins University Methods and compositions for treating schizophrenia
US10806717B2 (en) 2013-03-15 2020-10-20 The Johns Hopkins University Methods and compositions for improving cognitive function
AU2014228512A1 (en) 2013-03-15 2015-10-01 Agenebio, Inc. Methods and compositions for improving cognitive function
US9434724B2 (en) 2014-07-11 2016-09-06 Alpharmagen, Llc Quinuclidines for modulating alpha 7 activity
US10213586B2 (en) 2015-01-28 2019-02-26 Chrono Therapeutics Inc. Drug delivery methods and systems
CA2986598C (en) 2015-05-22 2023-09-26 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
US9724340B2 (en) 2015-07-31 2017-08-08 Attenua, Inc. Antitussive compositions and methods
JP2020503950A (ja) 2017-01-06 2020-02-06 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 経皮薬剤送達の装置及び方法
CA3101966A1 (en) 2018-05-29 2019-12-05 Morningside Venture Investments Limited Drug delivery methods and systems

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL107184A (en) * 1992-10-09 1997-08-14 Abbott Lab Heterocyclic ether compounds that enhance cognitive function

Also Published As

Publication number Publication date
MX9709721A (es) 1998-07-31
AU709784B2 (en) 1999-09-09
JP4060357B2 (ja) 2008-03-12
DE69617701T2 (de) 2002-10-17
PT846114E (pt) 2002-05-31
CA2223062C (en) 2010-10-12
IL118279A0 (en) 1996-09-12
KR19990022388A (ko) 1999-03-25
DE69617701D1 (de) 2002-01-17
DK0846114T3 (da) 2002-04-02
JP2000509011A (ja) 2000-07-18
IL118279A (en) 2006-10-05
EP0846114B1 (en) 2001-12-05
ATE210130T1 (de) 2001-12-15
HK1011866A1 (en) 1999-07-23
AU5804596A (en) 1996-12-30
EP0846114A1 (en) 1998-06-10
JP2007302691A (ja) 2007-11-22
CA2223062A1 (en) 1996-12-19
WO1996040682A1 (en) 1996-12-19
KR100484331B1 (ko) 2005-09-30

Similar Documents

Publication Publication Date Title
ES2171222T3 (es) Compuestos de eter heterociclico de 3-piridiloxialquilo utiles para regular la transmision sinaptica quimica.
ES2156998T3 (es) Compuestos de furopiridina, tienopiridina, pirrolopiridina y de pirimidina, piridazina y triazina relacionados utiles para controlar la transmision sinaptica quimica.
AR038427A2 (es) Compuestos 15-alquil-14-hidroxilo de marcfortina y parahercuamida
AU5169693A (en) Aminomethylene substituted non-aromatic heterocycles and use as substance p antagonists
FI970067A (fi) 2-/(dihydro)pyratsolyyli-3'-oksimetyleeni/-anilidit tuholaistentorjunta-aineina ja fungisideina
NO952253L (no) Tropon-substituerte, fenyloksazolidinon-antibakterielle midler
BR9509003A (pt) Composição absorvente de oxigênio
ATE206409T1 (de) N-(1-alkyl-5-phenyl-2,3,4,5-tetrahydro-1-h- benzo(b)(1,5)-diazepin-3-yl)-acetamide
PT1047690E (pt) Compostos eter e tioeter heterociclicos uteis no controlo da transmissao quimica sinaptica
ES2114619T3 (es) Nuevos analogos de la vitamina d.
TR199800624T1 (xx) Yeni 5-0- deosaminil 6-0-metil eritronolid a t�revleri, bunlar�n kullan�m�.
ES2196548T3 (es) Compuesto de hexahidro-1h-pirrolizina de sustitucion heterociclica en 7a utiles para regular la transmision sinaptica quimica.
ES2194102T3 (es) Nuevas n-(2,4-dioxo-2,3,4,5-tetrahidro-1h-1,5-benzodiazepin-3-il)-3-amidas.
ATE85978T1 (de) 2-quaternaer-pyridinalkylthio- oder pyridinalkenylthiosubstituierte carbapeneme, diese enthaltende zusammensetzungen und ihre zusammenstellungen mit dhp-inhibitoren.
ES2069831T3 (es) Nuevo compuesto de heptametilindano.
ES2188667T3 (es) 2',5'-oligoadenilatos de fosforotioato/fosfodiester y sus usos antivirales.
YU49316B (sh) Novi intermedijari, njihova primena u sintezi n,n'-premoštenih bisindolilmaleimida i farmaceutske formulacije
DK0397042T3 (da) Fremstilling af isoquinolinderivater
FI960588A (fi) Mikrobisideina käytettäviä tiokarbamoyyliyhdisteitä
FR2696746B1 (fr) Dérivés de l'acide benzèneborinique, leur préparation et leur utilisation comme intermédiaires de synthèse.
ES2108894T3 (es) Procedimiento para la preparacion de 5-cloroimidazoles eventualmente sustituidos en posicion 2.
ES2004215A6 (es) Procedimiento para preparar quinazolinas tetraciclicas
DK0794951T3 (da) Fremgangsmåder og mellemprodukter til fremstilling af cis(+)3-[4,6-dihydroxychroman-3-ylmethyl]-4-methoxyanilin
YU48660B (sh) Novi supstituisani 3-cijano-2-piridoni i novi postupci za njihovo dobijanje

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 846114

Country of ref document: ES